Introducing Antygen™ COVID-19 antibody detection platforms.

Our new suite of Antygen™ SARS-CoV-2 antibody detection platforms will enable researchers, pharmaceutical companies, and vaccine developers to closely monitor the immune effects induced by COVID-19 disease, vaccines, and therapies. We built them because all of our futures now depend on the body’s ability to make antibodies to SARS-CoV-2, the virus that causes pandemic COVID-19 disease.

Four new SARS-CoV-2 antibody detection platforms.

  • SARS-CoV-2 HuProt™: The world’s largest human protein library; now with SARS-CoV-2.  Profile autoantibodies versus >21,000 full-length human proteins alongside SARS-CoV-2 S1 receptor-binding spike and nucleocapsid proteins.
  • VirScan+ SARS-CoV-2:  Epitope-level antiviral antibody profiling of the human virome via T7 phage display and immunonprecipitation sequencing (PhIP-Seq) paired with our SMI or 2-in-1 SARS-CoV-2 microarrays.
  • SMI Protein Microarray: SARS-CoV-2, SARS-CoV, MERS-CoV, & Influenza proteins. Economic screening for antibodies to pandemic SARS-CoV-2 and other closely related viruses.

Contact us to learn more.

Fields marked with an * are required
First Name
Last Name
Company or Institution
Brief Project Description: